Non-invasive Prenatal Testing (NIPT) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Consumables, Instruments), By Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, Others), By Method (Ultrasound Detection, Biochemical Screening Testing, Cell-Free DNA Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests, Others), By Application (Trisomy, Microdeletion Syndrome, Others), By End User (Diagnostic Laboratories, Hospitals, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 5.25 Billion
CAGR (2026-2031)	7.78%
Fastest Growing Segment	Harmony
Largest Market	North America
Market Size (2031)	USD 8.23 Billion

Market Overview

The Global Non-invasive Prenatal Testing (NIPT) Market will grow from USD 5.25 Billion in 2025 to USD 8.23 Billion by 2031 at a 7.78% CAGR. Non-invasive Prenatal Testing (NIPT) is a sophisticated screening method that analyzes cell-free fetal DNA circulating in maternal blood to detect chromosomal aneuploidies such as trisomy 21, 18, and 13. The primary drivers propelling market growth include the rising average maternal age globally and a strong preference for safe, non-invasive procedures over traditional invasive diagnostic methods like amniocentesis. Additionally, the continuous expansion of test capabilities to screen for a broader range of conditions further supports adoption. According to the Association for Diagnostics & Laboratory Medicine, in 2025, research validated the expanded utility of these screenings by identifying Cytomegalovirus DNA in 2.1% of pregnancies, demonstrating the potential for comprehensive fetal health assessment.

Despite these favorable growth factors, the market faces a significant challenge regarding the high cost of testing and inconsistent reimbursement policies. This financial barrier restricts accessibility for the general population, particularly in developing economies and lower-income demographics, thereby limiting the universal implementation of NIPT as a standard routine prenatal care procedure and impeding global market saturation.

Key Market Drivers

Strategic Partnerships and Collaborations Among Key Market Players are pivotal in expanding the global footprint and capabilities of diagnostic providers within the NIPT sector. By acquiring regional laboratories and forming alliances, major companies are consolidating the market to enhance distribution networks and integrate specialized testing technologies into their portfolios. This consolidation allows for more efficient delivery of prenatal screening services to diverse patient populations and accelerates the availability of comprehensive women's health solutions. For instance, according to Labcorp, February 2025, in the 'Fourth Quarter and Full Year 2024 Results', the company announced 10 transactions in the full year 2024 to further establish its position as a trusted partner to health systems, significantly strengthening its presence in high-growth areas like women's health. These strategic moves not only broaden test menus but also improve infrastructure, fostering greater accessibility and market penetration.

The Rising Average Maternal Age Globally acts as a primary catalyst for the sustained demand for chromosomal aneuploidy screening. As delayed childbearing trends persist due to shifting socio-economic factors, the heightened clinical risk of chromosomal abnormalities in older mothers necessitates reliable, non-invasive fetal health assessments. According to the CDC, April 2025, in the 'Births: Provisional Data for 2024' report, the birth rate for women ages 40–44 increased 2% in 2024, underscoring this significant demographic shift. This increase in higher-risk pregnancies directly correlates with higher utilization rates of prenatal diagnostics as healthcare providers prioritize early detection. Consequently, diagnostic leaders are witnessing substantial volume surges; according to Myriad Genetics, February 2025, in the 'Fourth Quarter and Full-Year 2024 Financial Results', prenatal testing revenue grew 12% year-over-year, reflecting the robust uptake of these essential screenings driven by demographic pressures.

Download Free Sample Report

Key Market Challenges

The Global Non-invasive Prenatal Testing (NIPT) Market is substantially hindered by the high cost of testing and the lack of consistent reimbursement policies across different regions and insurance providers. While NIPT is recognized for its accuracy, significant out-of-pocket expenses create a severe barrier to entry for a large segment of the population, particularly in developing economies and among average-risk pregnancies where insurance coverage is frequently denied or limited. This financial disparity prevents the test from becoming a universal standard of care, effectively relegating it to a premium service rather than a routine medical procedure for all expectant mothers.

Consequently, market penetration remains uneven, with growth concentrated heavily in demographics that benefit from full financial coverage. According to the German Medical Association, in 2025, utilization data highlighted this discrepancy, revealing that only approximately 25% of pregnant women under the age of 26 accessed NIPT services due to funding limitations, compared to significantly higher adoption rates in age groups with established reimbursement coverage. This divide underscores how economic factors and inconsistent payer policies directly restrict the scalable expansion of the NIPT market, limiting its potential to reach saturation in the broader prenatal care sector.

Key Market Trends

The expansion of testing coverage to average-risk pregnancies represents a fundamental shift in the market, moving the consumer base from exclusively high-risk cases to a broader general population. This transition is distinct from demographic drivers, as it relies on the normalization of screening as a standard routine for all expectant mothers regardless of age, supported by increasing clinical validation for younger demographics. The uptake in this wider segment is rapidly accelerating test volumes, creating a new primary engine for industry expansion. Demonstrating this mass-market adoption, according to Natera, November 2025, in the 'Third Quarter 2025 Financial Results', the company processed approximately 893,600 tests, representing a 15.2% increase year-over-year, a surge driven largely by the robust penetration of these screenings into broader patient categories.

Simultaneously, the industry is advancing through the development of comprehensive multi-gene panel testing, which extends diagnostic capabilities beyond standard aneuploidy detection. Manufacturers are innovating assays that identify specific single-gene disorders and rare conditions previously undetectable via non-invasive methods, thereby addressing the clinical need for higher diagnostic yield in early pregnancy. This technological evolution enables the screening of complex inherited conditions, providing deeper genetic insights that facilitate earlier interventions and informed decision-making. Highlighting this advancement, according to Natera, October 2025, in the 'Natera Announces Expansion to 20 Genes for its Fetal Focus Single-Gene NIPT' press release, the company expanded its single-gene testing panel to cover 20 genes, significantly enhancing its capability to detect challenging homozygous mutations and severe early-onset disorders.

Segmental Insights

The Harmony segment currently stands as the fastest-growing product category within the Global Non-invasive Prenatal Testing (NIPT) Market, primarily driven by its specialized targeted assay technology. Unlike competitors employing broad whole-genome sequencing, Harmony utilizes a directed analysis approach that significantly lowers operational costs while maintaining high accuracy. This cost-efficiency makes the test uniquely scalable for the average-risk pregnancy population, a massive demographic increasingly prioritized by updated guidelines from the American College of Obstetricians and Gynecologists (ACOG). Furthermore, the extensive global distribution network of Roche has accelerated the test's accessibility, fueling its rapid adoption across diverse international markets.

Regional Insights

North America leads the Global Non-invasive Prenatal Testing (NIPT) Market due to high consumer awareness and a supportive regulatory environment. The region benefits from comprehensive insurance coverage that makes testing accessible to a wide demographic. Crucially, the American College of Obstetricians and Gynecologists (ACOG) recommends NIPT for all pregnant individuals, which has accelerated clinical integration beyond high-risk cases. Additionally, the concentration of major biotechnology firms within the United States facilitates rapid distribution and service expansion. This combination of clinical endorsement, financial accessibility, and industry presence secures the region's commanding market position.

Recent Developments

• In May 2025, BillionToOne, Inc. launched an expanded panel for its UNITY Fetal Risk Screen, enhancing its single-gene non-invasive prenatal testing capabilities. The expanded offering was designed to screen for five severe recessive conditions recommended by the American College of Obstetricians and Gynecologists (ACOG), as well as nine additional actionable conditions commonly found in specific populations. The test utilized the company's Quantitative Counting Template technology to assess fetal risk for these conditions directly from a maternal blood sample without requiring a paternal sample.
• In February 2025, Yourgene Health announced the launch of IONA Care+, a fully comprehensive non-invasive prenatal screening service available in the UK. The new service utilized the company's IONA Nx NIPT Workflow to provide screening for a wide range of genetic conditions, including the three most common trisomies, sex chromosome aneuploidies, and clinically relevant microdeletions. The launch expanded the company's menu-based approach, allowing healthcare providers and expectant parents to select from different screening options based on their specific needs.
• In November 2024, Myriad Genetics, Inc. announced that its Prequel Prenatal Screen was available to be performed as early as eight weeks into pregnancy. This capability was enabled by the company's proprietary AMPLIFY technology, which significantly increases the fetal fraction of cell-free DNA derived from the placenta. By offering screening earlier in the first trimester, the company aimed to provide expectant parents with critical genetic insights regarding chromosomal conditions sooner than standard timelines, which typically begin at nine or ten weeks gestation.
• In January 2024, Natera, Inc. announced the acquisition of select reproductive health assets from Invitae, specifically those related to non-invasive prenatal screening (NIPS) and carrier screening. Under the terms of the agreement, Natera made an upfront cash payment of $10 million, with additional potential milestone payments totaling up to $42.5 million. The transaction was designed to transition Invitae's reproductive health customers to Natera’s testing platforms, such as Panorama and Horizon, thereby consolidating Natera's position in the women's health and genetic testing market.

Key Market Players

• YOURGENE HEALTH Plc
• Illumina, Inc.
• Natera, Inc.
• F.Hoffman La Roche Ltd.
• Perkin Elmer Inc.
• Laboratory Corporation of America Holdings
• Eurofins LifeCodex GmbH
• Progenity, Inc.
• Genesis Genetics
• Quest Diagnostics Incorporated

By Product Type	By Test Type	By Method	By Application	By End User	By Region
Consumables Instruments	Materni 21 Harmony Panaroma Verifi NIFTY Others	Ultrasound Detection Biochemical Screening Testing Cell-Free DNA Maternal Plasma Tests Fetal Cells in Maternal Blood Tests Others	Trisomy Microdeletion Syndrome Others	Diagnostic Laboratories Hospitals Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Non-invasive Prenatal Testing (NIPT) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Non-invasive Prenatal Testing (NIPT) Market, By Product Type:

• Consumables
• Instruments

• Non-invasive Prenatal Testing (NIPT) Market, By Test Type:

• Materni 21
• Harmony
• Panaroma
• Verifi
• NIFTY
• Others

• Non-invasive Prenatal Testing (NIPT) Market, By Method:

• Ultrasound Detection
• Biochemical Screening Testing
• Cell-Free DNA Maternal Plasma Tests
• Fetal Cells in Maternal Blood Tests
• Others

• Non-invasive Prenatal Testing (NIPT) Market, By Application:

• Trisomy
• Microdeletion Syndrome
• Others

• Non-invasive Prenatal Testing (NIPT) Market, By End User:

• Diagnostic Laboratories
• Hospitals
• Others

• Non-invasive Prenatal Testing (NIPT) Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE